LOXL1 / Lysyl oxidase homolog 1 · IHC design guide

Design Immunohistochemistry for LOXL1

Plan LOXL1 paraffin IHC around matrix and plasma staining, with additional cytoplasmic signal (HPA tissue IHC). Use the catalog antibody at 0.5–1 μg/mL with chromogenic detection (datasheet PB9719; standard IHC practice).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for LOXL1 (IHC for LOXL1): expected localisation Extracellular matrix; additional cytoplasmic staining (HPA tissue IHC), antibody PB9719, validated IHC image, and IHC protocol steps — Printable **LOXL1** IHC protocol sheet — expected localisation Extracellular matrix; additional cytoplasmic staining (HPA tissue IHC), antibody PB9719, controls and protocol steps. Open the full LOXL1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

LOXL1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Extracellular matrix; additional cytoplasmic staining (HPA tissue IHC)
	Staining pattern	Matrix and plasma staining; some cytoplasm; glandular cells high (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet PB9719)
	Positive control ⓘ	Appendix+4 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep formalin fixation consistent across sections (standard IHC practice; not target-specific)
	Caveat	As a secreted protein, staining may differ from tissue RNA (HPA tissue IHC)
	Regulation	Regulation not specified (UniProt)
	Isoform / epitope	No isoforms annotated; map epitopes across the 95/96 cleavage (UniProt)

Section 1

Recommended LOXL1 IHC & IF Protocols

The catalog antibody’s IHC-P protocol is followed by two published LOXL1 IHC protocols with reported retrieval and detection details (PMC9087977; PMC9455728: Methods).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human prostatic cancer tissue; fixative not specified (datasheet PB9719)
Fixation	Image fixative and duration unreported (datasheet PB9719); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet PB9719); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB9719)
Primary antibody	Rabbit anti-LOXL1, 0.5-1μg/ml (datasheet PB9719)
Primary incubation	Overnight at 4 °C (datasheet PB9719)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9719)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	LOXL1-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Extracellular matrix and plasma positivity in several tissues with additional cytoplasmic expression. No signal in the no-primary control.

💡Decision noteStart with heat-mediated EDTA at pH 8.0 (PB9719 datasheet). If optimizing retrieval, the published alternatives are trypsin (PMC9087977: Methods) and heated citrate at pH 6.0 (PMC9455728: Methods).

Section 2

What Is the Expected LOXL1 Staining Pattern?

LOXL1 is a secreted protein found in extracellular space and matrix, with no transmembrane segment (UniProt Q08397 localisation and topology). In paraffin IHC, expect extracellular matrix and plasma positivity in several tissues, sometimes with cytoplasmic staining (HPA: tissue IHC, Approved). Reported positive cells include glandular cells in the appendix and colon and squamous epithelial cells in the esophagus (HPA: High in each).

What am I looking at on my slide?
Extracellular staining accompanies glandular staining in appendix or colon.	This fits the reported matrix and plasma pattern and High glandular staining in those tissues (HPA: tissue IHC). Score extracellular and cellular signal separately so their distribution remains clear (standard IHC practice).
Strong staining appears confined to nuclei, without the expected extracellular or glandular pattern.	A nucleus-only pattern does not fit LOXL1's reported extracellular location or the HPA tissue profile (UniProt Q08397 localisation; HPA: tissue IHC). Treat it as suspect and compare with controls before assigning specificity (standard IHC practice).
A cell population reported as negative stains strongly, such as respiratory epithelial cells in bronchus.	HPA reports LOXL1 as Not detected in those cells (HPA: bronchus). Consider cross-reactivity or endogenous detection activity; inspect the no-primary control and the expected positive tissue before interpreting the signal (standard IHC practice).
Diffuse chromogen covers cells and empty areas with little anatomical structure.	This is less convincing than HPA's cell-specific and extracellular pattern (HPA: tissue IHC). Check the no-primary control for detection background and review blocking, washes and development time (standard IHC practice).
No signal appears in appendix glandular cells despite intact tissue morphology.	Appendix glandular cells are reported High (HPA: appendix). A negative run there calls for checking the IHC-validated antibody, detection reagents and run controls before concluding that another specimen lacks LOXL1 (standard IHC practice).

💡Expected LOXL1 appearanceA credible positive result combines extracellular matrix or plasma staining with cell-specific signal, potentially High in appendix or colon glandular cells; isolated nuclear signal or uniform slide-wide chromogen is suspect (HPA: tissue IHC; HPA: appendix and colon; UniProt Q08397 localisation).

How each factor affects the staining
Secreted protein and compartment	LOXL1 has a signal peptide and is annotated in extracellular space and matrix (UniProt Q08397 topology and localisation). HPA also reports cytoplasmic expression, so extracellular and cellular staining can coexist (HPA: tissue IHC).
Processing	UniProt annotates signal peptide residues 1–25, propeptide residues 26–95 and a chain beginning at residue 96 (UniProt Q08397 processing). The supplied record gives no antibody epitope, so it cannot predict which processed forms the stain detects.
Tissue and cell selection	Appendix and colon glandular cells and esophageal squamous cells are High; stomach glandular cells are Medium (HPA: tissue IHC). Bronchial respiratory epithelium is Not detected (HPA: bronchus). Use the specified cells when comparing sections.
Evidence and antibody scope	HPA rates the tissue profile Approved and notes that RNA and protein locations can differ for a secreted protein (HPA: tissue IHC). HPA042111 is IHC Approved; that status alone does not establish the performance of another antibody (HPA: antibody validation).
IF/ICC Q&A: Is endoplasmic reticulum staining expected?	Yes, HPA reports approved endoplasmic reticulum localisation in ICC-IF (HPA: subcellular). The listed ICC-IF antibody is HPA063583, while HPA042111 is IHC Approved (HPA: antibody validation). Interpret each modality using its own evidence.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Appendix or colon glandular cells are negative.	These are High reference cells (HPA: appendix and colon); a failed run or weak detection is possible (standard IHC practice).	Review run controls, chromogen development and the IHC-validated antibody's stated IHC-P conditions before calling the specimen negative (standard IHC practice).
Bronchial respiratory epithelial cells stain strongly.	Those cells are Not detected in the HPA profile (HPA: bronchus); cross-reactivity or endogenous detection activity is possible (standard IHC practice).	Compare a no-primary control and a known-positive section, then judge whether the signal follows the reported cell pattern (HPA: tissue IHC; standard IHC practice).
The entire section has diffuse brown background.	Broad background obscures the anatomical distribution reported by HPA (HPA: tissue IHC). Detection background or overdevelopment may contribute (standard IHC practice).	Check the no-primary control; review blocking, washing and chromogen development using the same run conditions (standard IHC practice).
Staining is predominantly nuclear.	Nuclear-only staining conflicts with extracellular LOXL1 localisation and the reported tissue profile (UniProt Q08397 localisation; HPA: tissue IHC).	Compare compartment and cell type against a positive control and inspect no-primary staining before accepting specificity (standard IHC practice).
Extracellular signal and cell-associated signal receive one score.	HPA reports extracellular matrix and plasma positivity with additional cytoplasmic expression (HPA: tissue IHC). A single score can hide which component changed.	Record compartment, stained cell type and intensity separately in each section (standard IHC practice).
An ICC-IF endoplasmic reticulum image seems inconsistent with extracellular IHC.	HPA reports endoplasmic reticulum in ICC-IF and extracellular matrix or plasma staining in tissue IHC (HPA: subcellular; HPA: tissue IHC).	Compare each result with its modality-specific HPA pattern and antibody validation, without treating an ICC-IF image as an IHC control (HPA: antibody validation; standard IHC practice).

Source: UniProt Q08397 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing LOXL1 staining

IHC analysis of LOXL1 using anti-LOXL1 antibody (PB9719). LOXL1 was detected in a paraffin-embedded section of human prostatic cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1 μg/ml rabbit anti-LOXL1 Antibody (PB9719) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1022) with DAB as the chromogen.

PB9719 · IHCIHC analysis of LOXL1 using anti-LOXL1 antibody (PB9719). LOXL1 was detected in a paraffin-embedded section of human prostatic cancer tissue

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000129038-LOXL1/tissue/cerebral+cortex#imid_10912883

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000129038-LOXL1/tissue/colon#imid_10910057

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000129038-LOXL1/tissue/liver#imid_10910058

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000129038-LOXL1/tissue/kidney#imid_10910067

HPA ICC-IF BJ [Human fibroblast] — LOXL1 (HPA063583)

HPA · ICC-IF BJ [Human fibroblast]Human Protein Atlas immunofluorescence, BJ [Human fibroblast], antibody HPA063583; green = LOXL1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for LOXL1 IHC & IF

🧪Run appendix first: its glandular cells should stain (HPA: High in appendix glandular cells). Use adipose tissue as the negative tissue, assessing adipocytes (HPA: Not detected in adipose adipocytes); on the appendix slide, treat unstained neighboring cells as a background reference only, since extracellular LOXL1 may extend beyond producing cells (UniProt Q08397 localization).

Positive control tissue: Appendix (Glandular cells, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show LOXL1 in BJ [Human fibroblast], Rh30, U2OS, with annotated localisation: Endoplasmic reticulum (approved) (HPA subcellular).

Technical controls: Include no-primary (secondary-only), host- and isotype-matched rabbit IgG, and LOXL1-knockout tissue or a validated peptide-block control (PB9719 caption: rabbit primary; standard IHC controls). Check endogenous peroxidase and biotin signal when interpreting appendix DAB staining (PB9719 caption: biotin-based DAB detection; standard IHC practice).

⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected PB9719 paraffin-section caption does not state a fixative (PB9719 caption). That caption uses heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required; the supplied evidence does not establish whether frozen sections or IF would be easier (PB9719 caption). In appendix, luminal material and endogenous biotin or peroxidase can complicate interpretation of glandular DAB signal (HPA: appendix glandular cells; PB9719 caption: biotin-based DAB detection; standard IHC practice).

HPA tissue IHC evidence for LOXL1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Secreted protein, tissue location of RNA and protein is expected to differ.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Appendix	Glandular cells	High	Protein (IHC)	HPA →
Colon	Glandular cells	High	Protein (IHC)	HPA →
Esophagus	Squamous epithelial cells	High	Protein (IHC)	HPA →
Rectum	Glandular cells	High	Protein (IHC)	HPA →
Small intestine	Glandular cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	Not detected	Protein (IHC)	HPA →
Caudate	Glial cells	Not detected	Protein (IHC)	HPA →
Endometrium	Cells in endometrial stroma	Not detected	Protein (IHC)	HPA →

Section 3

Advanced LOXL1 IHC Tips

Troubleshoot LOXL1 chromogenic IHC by checking retrieval, compartment-specific staining and extracellular matrix signal before comparing sections.

Which retrieval conditions should I use when LOXL1 staining is weak in paraffin sections?

Use heat-mediated retrieval in EDTA at pH 8.0 as the starting condition (datasheet PB9719). The selected paraffin-section example used that condition before overnight incubation at 4°C with 1 μg/ml primary antibody (datasheet PB9719). If staining is weak, compare a small retrieval time series while keeping section thickness, detection and exposure to chromogen constant (standard IHC practice). Include a section processed without primary antibody to distinguish retrieval-related background from antibody staining (standard IHC practice). Assess extracellular matrix as well as cytoplasm, because both patterns are reported in tissue (HPA tissue IHC profile).

How should I troubleshoot fixation-dependent loss of LOXL1 staining?

The selected image identifies paraffin embedding but does not report its fixative, so LOXL1-specific fixation sensitivity is unknown for PB9719 (datasheet PB9719 caption). Record fixative, fixation duration and processing history for every specimen before comparing staining intensity (standard IHC practice). When archival blocks differ, compare matched specimens processed together and use the same EDTA pH 8.0 retrieval condition (datasheet PB9719; standard IHC practice). Inspect tissue preservation and nonspecific background alongside signal; either can change how a section is scored (standard IHC practice). Do not assign an apparent difference to LOXL1 expression until processing differences have been assessed (standard IHC practice).

Should LOXL1 staining be extracellular, cytoplasmic or both?

LOXL1 is secreted into the extracellular space and matrix and has no transmembrane segment (UniProt Q08397 subcellular location and topology). Tissue IHC reports extracellular matrix and plasma positivity with additional cytoplasmic expression (HPA tissue IHC profile). A cytoplasmic component can therefore be recorded, but score it separately from extracellular deposits so one compartment does not mask changes in the other (HPA tissue IHC profile; standard IHC practice). Mark vessels and tissue boundaries on the reviewed section before assigning matrix signal to nearby cells (standard IHC practice). An exclusively nuclear pattern conflicts with the supplied localisation evidence and warrants review of controls and morphology (UniProt Q08397 subcellular location; HPA tissue IHC profile).

Can precursor processing change what the LOXL1 antibody detects in tissue?

LOXL1 has a signal peptide at residues 1–25, a propeptide at 26–95 and a processed chain at 96–574 (UniProt Q08397 processing). The record lists 0 isoforms and 0 glycosylation sites; it also lists a modified residue at 512 (UniProt Q08397 isoforms, glycosylation and modified residues). The supplied PB9719 caption does not identify its epitope, so it cannot establish whether staining represents precursor, propeptide-containing protein or processed chain (datasheet PB9719 caption; UniProt Q08397 processing). Check the antibody's documented immunogen or epitope before making a processing-specific claim (standard IHC practice). Report observed compartments without treating staining intensity as a direct measure of processing (standard IHC practice).

How can I use IF to check an ambiguous LOXL1 IHC pattern?

Use IF as a separate validation experiment and multiplex LOXL1 with a marker for the cell population being assessed (standard IF practice). Choose fluorophores after checking each tissue's autofluorescence and include single-label controls to evaluate bleed-through (standard IF practice). For an antibody epitope inside cells, permeabilise after fixation; for an extracellular epitope, assess staining without permeabilisation first, because LOXL1 is secreted and lacks a transmembrane segment (UniProt Q08397 subcellular location and topology; standard IF practice). HPA reports an approved endoplasmic reticulum location in its subcellular data, while tissue IHC also reports matrix positivity (HPA subcellular; HPA tissue IHC profile). Compare compartments without assuming the IF result transfers directly to paraffin-section IHC (standard IHC/IF practice).

What should I change when matrix or plasma staining obscures specific LOXL1 signal?

Extracellular matrix and plasma positivity are reported for LOXL1, so diffuse staining in those compartments is not automatically nonspecific (HPA tissue IHC profile). The selected PB9719 example used 10% goat serum, 1 μg/ml primary antibody and a biotin-based DAB detection workflow (datasheet PB9719 caption). Run a no-primary control, apply a peroxidase block and inspect background associated with biotin-based detection before adjusting the primary concentration (standard IHC practice). Keep chromogen development consistent across comparison sections and review them with the same illumination settings (standard IHC practice). If background persists, compare antibody concentrations against preservation of the expected compartment pattern (UniProt Q08397 subcellular location; standard IHC practice).

How should I quantify LOXL1 when both cells and matrix stain? ⚠ ANSWER MARKED FOR VERIFICATION

Score cellular staining with the percentage of positive cells or an H-score, recording the cell population and intensity criteria before reviewing groups (standard IHC practice). Measure extracellular deposits separately as positive area or signal density per mm² of evaluable matrix (standard IHC practice). Normalise each measure to its relevant denominator: counted cells for cellular scores and measured, viable tissue or matrix area for deposits (standard IHC practice). Exclude folds, tears and necrosis using the same rules across sections (standard IHC practice). Keep these readouts distinct because tissue IHC reports both extracellular and cytoplasmic LOXL1 patterns (HPA tissue IHC profile).

How can I distinguish true LOXL1 staining from artefact in a paraffin section?

Give greater weight to reproducible extracellular matrix signal or plausible cytoplasmic staining than to an isolated nuclear pattern (UniProt Q08397 subcellular location; HPA tissue IHC profile). Check whether staining follows tissue morphology rather than section edges, folds or necrotic debris (standard IHC practice). Use a no-primary control to examine endogenous enzyme or detection background, particularly when interpreting DAB signal from the selected biotin-based workflow (datasheet PB9719 caption; standard IHC practice). Compare the relevant cell population with HPA's reported tissue patterns; for example, appendix glandular cells are high, whereas bronchus respiratory epithelial cells are not detected (HPA tissue IHC). Because LOXL1 is secreted, staining adjacent to a cell does not alone establish that the cell produced it (UniProt Q08397 subcellular location; HPA tissue IHC reliability description).

Boster reagents

Best LOXL1 / Lysyl oxidase homolog 1 IHC Antibodies

PB9719 has real IHC data from a human paraffin-embedded prostatic cancer section (PB9719 image caption); no IF image is provided (catalog image list).

Real IHC data

Anti-LOXL1 Antibody ®

Cat # PB9719

View product →

PB9719 is listed for human IHC and WB (catalog applications and reactivity). Its IHC image shows staining in a human paraffin-embedded prostatic cancer section; the fixative is unreported (PB9719 image caption).

Which to pick: Choose PB9719 for human paraffin-section IHC, supported by its own IHC image caption and application listing (PB9719 image caption; catalog applications). No listed SKU is validated for IF/ICC or other species, and PB9719’s clonality is unreported (catalog applications, reactivity and clone field).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q08397 (LOXL1_HUMAN, Lysyl oxidase homolog 1).
Human Protein Atlas. LOXL1 tissue IHC expression (reliability: Approved).
Human Protein Atlas. LOXL1 subcellular location (ICC-IF): Localized to the endoplasmic reticulum..
Human Protein Atlas. LOXL1 antibody validation summary (2 antibodies).
Effects of parathyroid hormone (1-34) on the regulation of the lysyl oxidase family in ovariectomized mice. RSC advances 2018 — PMC9087977.
Molecular alterations underlying the enhanced disruption of spermatogenesis by 2,5-hexanedione and carbendazim co-exposure. Reproductive toxicology (Elmsford, N.Y.) 2012 — PMC3327768.
Sex-Linked Skeletal Phenotype of Lysyl Oxidase Like-1 Mutant Mice. Calcified tissue international 2016 — PMC8627178.
Correlation of Matrisome-Associatted Gene Expressions with LOX Family Members in Astrocytomas Stratified by IDH Mutation Status. International journal of molecular sciences 2022 — PMC9455728.
PubMed PMID:7689553 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:16572171 — UniProt-cited evidence.